{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:22:22Z","timestamp":1786990942235,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ijrobp.2018.06.008","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:36:19Z","timestamp":1529350579000},"page":"287-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer"],"prefix":"10.1016","volume":"102","author":[{"given":"Himanshu R.","family":"Lukka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah W.","family":"Bruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Bahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen A.F.","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat J.","family":"Kudchadker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee E.","family":"Ponsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A.","family":"Seaward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian S.","family":"Dayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darindra D.","family":"Gopaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff M.","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guila","family":"Delouya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving D.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Mack","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne H.","family":"Pinover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Amanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Kachnic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2018.06.008_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib3","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/cncr.29362","article-title":"Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial","volume":"121","author":"Bruner","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0360-3016(98)00029-7","article-title":"Sublethal damage repair times for a late-responding tissue relevant to brachytherapy (and external-beam radiotherapy): Implications for new brachytherapy protocols","volume":"41","author":"Brenner","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0360-3016(03)00132-9","article-title":"What hypofractionated protocols should be tested for prostate cancer?","volume":"56","author":"Fowler","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0360-3016(86)90081-7","article-title":"Tumor radioresponsiveness versus fractionation sensitivity","volume":"12","author":"Thames","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0360-3016(02)03828-2","article-title":"How low is the alpha\/beta ratio for prostate cancer?","volume":"55","author":"Wang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0360-3016(03)00747-8","article-title":"The low alpha\/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?","volume":"57","author":"Wang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib11","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation scheduled in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high dose intensity modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib13","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ijrobp.2008.05.059","article-title":"Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial","volume":"73","author":"King","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib16","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 2","key":"10.1016\/j.ijrobp.2018.06.008_bib17","first-page":"S43","article-title":"Hypofractionated radiotherapy for low risk prostate cancer: Preliminary results of a phase I\/II trials","volume":"92","author":"Menkarios","year":"2009","journal-title":"Radiother Oncol"},{"issue":"Suppl","key":"10.1016\/j.ijrobp.2018.06.008_bib18","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.ijrobp.2009.07.201","article-title":"A phase I\/II trial of increasingly hypofractionated radiation therapy for prostate cancer","volume":"75","author":"Ritter","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.clon.2008.08.006","article-title":"Phase I\/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: Early results of pHART3","volume":"20","author":"Tang","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/A:1015240103565","article-title":"Validity and responsiveness of the EQ5D as a measure of health-related quality of life in people\u00a0enrolled in an AIDS clinical trial","volume":"11","author":"Wu","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib21","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2002.20.2.557","article-title":"Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer","volume":"20","author":"Wei","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1748-717X-8-118","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years","volume":"8","author":"Katz","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13014-016-0758-8","article-title":"Toxicity and quality of life report of phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer","volume":"12","author":"Boyer","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1748-717X-9-148","article-title":"Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer","volume":"9","author":"Chen","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.prro.2017.08.004","article-title":"A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life","volume":"8","author":"Jackson","year":"2018","journal-title":"Practical Radiation Oncology"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","article-title":"The randomization and stratification of patients to clinical trials","volume":"27","author":"Zelen","year":"1974","journal-title":"J Chron Dis"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib28","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib29","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1200\/JCO.2007.11.4645","article-title":"National Cancer Institute of Canada Clinical Trials Group. Lessons learned in the assessment of health-related quality of life: Selected examples from the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Brundage","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib30","series-title":"Applied Logistic Regression","author":"Hosmer","year":"2000"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Meier P. Non-parametric estimation from incomplete observations","volume":"53","author":"lan EL","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib32","series-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.radonc.2015.07.016","article-title":"Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy","volume":"116","author":"Evans","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.06.008_bib34","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/cncr.30519","article-title":"Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer","volume":"123","author":"Dess","year":"2017","journal-title":"Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618309611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618309611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T20:58:42Z","timestamp":1536699522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301618309611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0360301618309611"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.06.008","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}